Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2016; 22(41): 9044-9056
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9044
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9044
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
Nina Weiler, Stefan Zeuzem, Martin-Walter Welker, Universitätsklinikum Frankfurt, Medizinische Klinik 1, 60590 Frankfurt, Germany
Author contributions: Weiler N and Welker MW contributed to literature research and wrote the paper; Zeuzem S revised the paper.
Conflict-of-interest statement: Weiler N, Consultancies/speaker’s bureau for Astellas, Novartis; Zeuzem S, Consultancies/speaker’s bureau for Abbvie, BMS, Gilead, Janssen, Merck; Welker MW, Consultancies/speaker’s fees: AbbVie, Amgen, Bayer, BMS, Gilead, Novartis, Roche. Travel Support: AbbVie, Astellas, Bayer, BMS, Novartis, Janssen, Roche.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Martin-Walter Welker, MD, Universitätsklinikum Frankfurt, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. welker@med.uni-frankfurt.de
Telephone: +49-69-63016557 Fax: +49-69-63015716
Received: May 14, 2016
Peer-review started: May 17, 2016
First decision: July 12, 2016
Revised: August 9, 2016
Accepted: October 19, 2016
Article in press: October 19, 2016
Published online: November 7, 2016
Peer-review started: May 17, 2016
First decision: July 12, 2016
Revised: August 9, 2016
Accepted: October 19, 2016
Article in press: October 19, 2016
Published online: November 7, 2016
Core Tip
Core tip: Chronic hepatitis C is a major reason for development of cirrhosis and a leading cause for liver transplantation. The development of direct-acting antiviral agents (DAA) offered new therapeutic options for patients with advanced cirrhosis and liver graft recipients. This review gives a high topical summary of most current therapeutic options of DAA-based antiviral therapy in patients with hepatitis C virus associated cirrhosis before and after liver transplantation.